Global

Bazelet™

Research

We are a life science company researching novel plant-based food ingredients and medicines, nutraceuticals, cosmeceuticals, and other products that improve human, animal and environmental health.

Clinical Research

From our Columbia, Maryland clinical offices, Bazelet™ CMO Dr. Francisco Ward will lead a panel of physicians conducting a host of clinical research projects based on PECSA™ and non-psychotropic cannabis therapies. 

 

Globally, scientific research of the cannabis sativa L plant has been and remains illegal because of the Controlled Substance Act. This has created a decades-long pent-up demand for diverse applications of cannabinoid research. In 2016, the DEA announced that it was amending its longstanding policies to allow additional parties to grow cannabis for the DEA for clinical research purposes. However, as of March 2022, there are only three DEA approved bulk manufactures in the US.  

“We are opening our genetic library and our genetic sequencing knowledge to more than 575 fellow DEA registered research entities, encouraging their support for rigorous scientific and medical research. This is a special time in cannabis history and moreover a special time in human health history.” said, Dr. Francisco Ward, DO, Chief Medical Officer for Bazelet™, and physiatrist. He added “I look forward to collaborating with colleagues, scientists, DEA registrants and patients everywhere, to study, innovate and access the potential of our unique plants and products in the areas of traumatic brain injury, neurodegenerative diseases, auto-immune and inflammatory diseases, vascular diseases, chronic pain, psychiatric conditions such as including anxiety, depression, sleep, addiction, delusional states, post-traumatic stress disorder (PTSD) and, most recently, its ability to enhance the care and treatment of Covid-19.”  

CASE STUDY:    PECSA™ as an Anti-COVID-19 agent.

PECSA’s primary cannabinoid is Cannabigerol Acid “CBGA”. A recent laboratory study at Oregon State University found that CBGA binds to the SARS-CoV-2 spike protein, blocking a critical step in the process the COVID-19 virus uses to infect people. Essentially, it shows that CBGA may prevent coronavirus from entering human cells. 

 

The study, published in the Journal of Natural Products, was a collaboration between scientists at Oregon Health & Science University and Oregon State University.

 

For more information, see the news release from Oregon State University.

Animal Research

Bazelet™ is seeking relationships with public and private sector institutions in the area of livestock and animal research.

 

Our work includes studying the effects of non-psychotropic cannabis on animal health and wellness. Benefits are far reaching and include decreasing stress, improved immune health and increased production from our livestock.

 

Pet research looks at the use of non-psychotropic cannabis protein and cannabinoids in our pet food supply.

 

Excitedly, our animal research also includes use of PECSA and Cannabigerol to increase alertness and cognitive function in competitive horses including racehorses, rodeo and polo horses. To learn more about this exciting and promising area of research or to sponsor a research project, please click here.

Environmental Research

Breeding and selecting for enhanced phytoremediation properties Cannabis Satvia L. is a hyperaccumulating plant species. “Agro-mining” or utilization of heavy metal accumulating capabilities some plants possess, sustainably extract minerals of interest and remediate contaminated or toxic soils.

 

  • Remediating heavy metals, hydrocarbons, VOCs, PCBs, PAHs. Valuable materials may be extracted from harvested biomass and recycled
  • Structuring soil, water retention, increasing biodiversity and fertility for succession planting (Show efficacy of intercropping Cannabis Sativa L)

Aim: Increased Biomass production –> More CO2 Sequestered

Plant Research

Bazelet™ is breeding cannabis plants from registered and globally approved varieties including the European Union (EU) and the Association of Official Seed Certifying Agencies (AOSCA), and new plant genetics that utilize [CRISPR]Cas9 to further advance our unprecedented cannabis genetics library.

 

Bazelet™ and Cornell University have a multi-year research agreement and more recently the University of Maryland. Later in 2022, Bazelet™ and Cornell are to begin valuable plant science research, expanding Zero-THC Cannabis varieties for New York State.

 

Bazelet™ is creating enhanced characteristics in the plant while maintaining a non-GMO plant genetic.

 

Cannabis-ZERO™, a result of Bazelet’s plant research and the establishment of the world’s first Zero-THC cannabis plants. Cannabis-ZERO™ is unlocking the diverse medical and industrial uses of cannabis but with zero illegal substances, zero-psychotropics, zero THC.

 

Cannabis Zero™ genetics are next generation cannabis plants, federally legal, ready for commercialization because they are scientifically different from marijuana and hemp, a new subspecies of cannabis.

Food and Beverage Research

Specialized research dedicated to helping food and beverage producers, operators, consumers and regulators about food and beverages derived from Cannabis-Zero products, including PECSA.

 

Our science-backed data is helping Bazelet develop and commercialize food and beverage products that include cannabinoids derived from Cannabis-Zero Plants.

Scientifically Safe, complaint food and beverage products

The diverse and rapidly evolving nature of the Cannabis/Cannabinoid space requires extensive medical knowledge, including the EndoCannabinoid System (ECS) and in-depth scientific knowledge of the cannabis Sativa L. plant (CSL) biome, and its molecular constituents.

 

We are helping test, validate and build sustainable, efficient agri-food supply chains by delivering safe, nutritious food in today’s fast-changing consumer market.

Research with Federal Agencies

Bazelet’s team of medical doctors is led by Dr. Francisco Ward DO., NBPAS-PM&R/PM, who has conducted 14 different Federally funded clinical trials in his career. Bazelet’s research team is led by David Grand, who is known for bringing non-psychoactive cannabis sativa to the forefront of advanced cannabis research, globally. Both are very well known in the research communities worldwide.

Together, with other members of the Bazelet team, they are advocating for US patent approved cannabis sativa L. species being accepted into the food & beverage, beauty & personal care, and over the counter drug markets. Through years of collaborative efforts with the appropriate federal agencies, they have successfully brought to market legal cannabis sativa.

Clinical Trials

Bazelet Health Systems will research, test and co-develop food and beverage products for the healthcare and consumer product sectors.

With less than 13% of medical schools teaching the human endocannabinoid system, we have the responsibility to expand access to foundational endocannabinoid knowledge, including new cannabis and cannabinoid-derived clinical research findings as published regularly by American Journal of Endocannabinoid Medicine (AJEM).

Kenny Watkins, AJEM Publisher

.A clinical vignette by Dr. Francisco Ward, DO, Chief Medical Officer for BazeletTMThe Endocannabinoid system (ECS) is a sophisticated group of ligands, their receptors, and signaling pathways that are involved in homeostatic regulation of a variety of physiological processes, including emotional responses, behavioral reactivity, and social interactions (anxiety, grief, stress, depression, post-traumatic stress disorder, insomnia) as well as maintenance of energy homeostasis, for potential management of diabetes and hyperlipidemia (triglycerides and cholesterol), with potential benefits in oncology (colon cancer and polyps), anti-inflammatory (inflammatory bowel disease) and neurodegenerative conditions (Huntington’s disease). Cannabinoid receptors in the hypothalamus control gonadotropin-releasing hormone and oxytocin release, both of which contribute to normal sexual functioning.
 
Reviews of the pre-clinical literature for CBG have also shown some preliminary ability to ameliorate cancer tumors, substance use disorder, pain, as well as acting as an anti-inflammatory, anti-oxidant, analgesic, anti-arthritic, cognitive enhancing, anti-fatigue, antidepressant, antidiabetic, as well as other clinical effects. CBG appears to hold benefits for neurologic disorders, especially degenerative and inflammatory conditions.
 
CBG acts on targets including cyclooxygenase (COX) enzymes, α-2 adrenoceptor, CB1, CB2, G-protein coupled receptors (GPCR) such as serotonin 5-HT1A receptors, peroxisome proliferator-activated receptors (PPAR), transient receptor potential channels (TRPV, TRPA, TRPM), cys- loop ligand- gated ion channels such as GABA receptors, and the fatty acid amide hydrolase (FAAH) enzyme among others, which may contribute positively to lipid metabolism and metabolic syndrome. It is not known to have any psychomotor impact making it more suitable for daily use and higher doses as an analgesic.

The acute anxiolytic effects of CBG at lower doses are thought to involve 5-HT 1A activation. TRPV1 activity seems to be unique to CBG and CBD as well as a few other minor cannabinoids, but THC does not interact with this receptor channel. Another potential mechanism through which CBG produces anxiolytic effects is due to the action of the endogenous cannabinoid anandamide (EAE) in the brain, which has been associated with the “runner’s high.”  CBD and CBG may increase cannabinoid receptor activation indirectly by elevating endocannabinoid levels through its action on endocannabinoid (ECS) metabolism, which is homeostatic. Both CBD and CBG have the ability to inhibit fatty acid amide hydrolase (FAAH) enzyme, which metabolizes EAE, resulting in indirectly increasing CB1 receptor activation, which may also have a favorable effect on lipid metabolism and insulin sensitivity. CB1 receptor activation has been thought to mediate the ability of CBD and CBG to regulate long-term learned fear processing. ECS signaling is part of an endogenous anxiolytic neuro-modulatory system, thus inhibition of FAAH activity is a potentially promising therapeutic approach for reducing anxiety-related symptoms. 
CBG has also shown some promise in colorectal polyps, as an antineoplastic, as well as with endometriosis.


Current research indicates that cannabis including THC, in general, has a low overall risk with short-term use, outside of concerns over a cannabis use disorder (due to psychoactive, THC), its major complications are very limited, without documented overdose deaths.

CBG appears to hold benefits for neurologic disorders, especially degenerative and inflammatory conditions based on its CB2 binding, which is found in primarily in immunologic cells. The activity of CBG at 5-HT1A receptors may drive its neuroprotective, anti-depressive, and anxiolytic benefits, although the mechanism of action by which CBG decreases anxiety and increased the duration of sleep is still unclear. It has minimal adverse effects due to its limited cytochrome P450 hepatic metabolism pathways, and it has less predicted drug to drug interactions than CBD.  It appears that CBG with chronic use and at higher doses is nontoxic, does not induce changes in food intake or catalepsy, does not affect physiological measures, and does not alter psychomotor or psychological functions. Thus far, CBG demonstrates no potential for abuse or dependence in humans and has no apparent “street value.”  There is a hypothesized “entourage” effect of the combination of all cannabinoids (with or without THC) taken as a “spectrum” of ingredients has a greater effect that each individual cannabinoid alone for a therapeutic response. In addition, the route of administration as well as the dose intervals, may contribute to the clinical effect, such that vaporized CBG potentially may have minimal psychotropic properties (predictably, topical use would have a negligible effect) in some preparations, with a more rapid onset and shorter duration of effect. The most notable benefit of cannabis in any form is its safety, with no reports of lethal overdose with any of the cannabinoids. More research is needed to clarify any possible long-term risks and harms of CBG.

Neuropsychiatric anxiety disorders include generalized anxiety disorder (GAD), social anxiety disorder (SAD; also known as social phobia), specific phobia, panic disorder, and agoraphobia. Obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) and mood disorders including depression that can overlap with anxiety but ,have other distinct features; they can also be modulated by serotonergic and noradrenergic pathways . In addition, chronic pain may include psychological symptoms including catastrophizing, somatization, and kinesiophobia (fear of activity).  Substance use (chemical dependency) disorders are also associated with these other psychiatric condition

Bazelet Landrace Genetics

The origin of the cannabis plant (Cannabis Sativa L.) is thought to be located  around the Indo-China plate over 9000 years ago where present day Tibet is located.  This is based on evidence found in June 2019 by a team of researchers.

Cannabis Sativa L. has evolved and adapted because of its ability to acclimate to various environments. The absence of chronologically recorded data regarding the usage of cannabis in history remains a significant reason for an almost non existent archive of naturally occurring, domesticated, imported, or acclimatized ” varieties from around the world.

At Bazelet™, we are part of the true Landrace Cannabis population. Thus, it is not only a privilege, but also a humble duty to present our observations by carefully assessing the acquired data from the cannabis hotspots around the world in a clear, concise, and scientific manner.

The Bazelet™ classification system and nomenclature for Landrace Cannabis varieties are based upon three major categories influencing the terroir which are, geographical positioning (latitude and altitude), flowering duration, and human impact. Using this classification system, Bazelet and our team of horticulture scientists are able to instantly draw a broad and comprehensive picture around the important details of the Cannabis variety in question.

Join Us

Register Now to Reserve A Slot. Looking forward to See You!